Topics

Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma.

08:00 EDT 12th September 2019 | BioPortfolio

Summary of "Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma."

Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation, including immunoglobulin E (IgE)-mediated allergic inflammation in asthma. In the LIBERTY ASTHMA QUEST (NCT02414854) study, dupilumab reduced severe asthma exacerbations and improved forced expiratory volume in 1 second (FEV) in patients with uncontrolled, moderate-to-severe asthma with greater efficacy observed in patients with elevated type 2 inflammatory biomarkers (blood eosinophils and fractional exhaled nitric oxide) at baseline.

Affiliation

Journal Details

This article was published in the following journal.

Name: The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Pages:

Links

DeepDyve research library

PubMed Articles [34485 Associated PubMed Articles listed on BioPortfolio]

Dupilumab: Basic aspects and applications to allergic diseases.

Interleukin (IL)-4 and IL-13, signature type 2 cytokines, exert their actions by binding to two types of receptors sharing the IL-4R α chain (IL-4Rα). Since IL-4 and IL-13 play important and redunda...

Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.

Dupilumab, a human monoclonal antibody, blocks the shared receptor unit for interleukin-4 and interleukin-13. International phase II and III studies have evaluated the efficacy and safety of dupilumab...

Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.

The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD).

Efficacy and Safety of treatment with dupilumab for severe asthma.

Dupilumab, a fully human monoclonal antibody against Interleukin-4 receptor α is approved as add-on maintenance treatment for inadequately controlled type 2 severe asthma. This systematic review eval...

Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.

Dupilumab (monoclonal antibody inhibiting IL-4/IL-13 signalling) is approved for use in adolescents aged ≥ 12 years with inadequately controlled moderate-to-severe atopic dermatitis (AD). Dupilumab ...

Clinical Trials [11826 Associated Clinical Trials listed on BioPortfolio]

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in patients with moderate to severe, uncontrolled asthma Secondary Objective: To eva...

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis

Primary Objective: To evaluate the efficacy of dupilumab monotherapy compared to placebo treatment in adult patients with moderate-to-severe atopic dermatitis (AD). Secondary Objec...

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Patients With Asthma

The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma. The secondary objectives of the study ...

2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD). ...

Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma

The DupiMorph study evaluates the efficacy of Dupilumab in localized scleroderma patients. Dupilumab is approved in the US and EU for the treatment of moderate/severe atopic dermatitis and...

Medical and Biotech [MESH] Definitions

A selective beta-1-adrenergic partial agonist. Because it is a partial agonist (DRUG PARTIAL AGONISM) it acts like an agonist when sympathetic activity is low and as an antagonist when sympathetic activity is high. It reduces MYOCARDIAL ISCHEMIA and improves ventricular function in patients with mild to moderate heart failure. In patients with severe heart failure it has been shown to produce benefits in systolic and diastolic function.

A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.

Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.

An opioid analgesic used similarly to MORPHINE in the control of moderate to severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1097)

For-profit enterprise with relatively few to moderate number of employees and low to moderate volume of sales.

Quick Search


DeepDyve research library

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...


Searches Linking to this Article